摘要
心力衰竭(简称心衰)是各种心脏疾病的末期表现和最重要的死因,在全球有千万患者,目前对于HFrEF,虽经合理化治疗,其预后并未得到显著的改善,目前,对心衰患者的药物治疗一直处于研究中,达格列净为SGLT-2抑制剂的一种,在用于糖尿病患者的降糖治疗中发现其可以降低心血管不良事件的发生率,随后有研究表明达格列净可显著降低心衰患者的住院率,死亡率、各种复合事件,可以使得心衰患者的预后得到很好地改善,本文就达格列净对心衰患者的获益做一综述。
Heart failure (referred to as heart failure) is the final manifestation and the main cause of death of cardiovascular diseases. There are millions of patients in the world. At present, although HFrEF has undergone strict standardized treatment, the survival rate was not obviously improved. At present, the drug treatment for patients with heart failure has been under study. Dapagliflozin belongs to SGLT-2I, which can reduce the incidence of cardiovascular adverse events in hypoglycemic treatment of diabetic patients. After a large study, it was shown that Dapagliflozin can significantly reduce the hospitalization rate of patients with heart failure, and the mortality rate and various complex events can improve the prognosis of patients with heart failure. This article reviews the benefits of Dapagliflozin to patients with heart failure.
出处
《临床医学进展》
2021年第11期5322-5326,共5页
Advances in Clinical Medicine
